Brief: Concord Biotech Gets Abbreviated New Drug Application Approval For Tofacitinib Tablets, 5 Mg And 10 Mg
10/06/2026 06:06
BRIEF-Concord Biotech Gets Abbreviated New Drug Application Approval For Tofacitinib Tablets, 5 Mg And 10 Mg June 10 (Reuters) - Concord Biotech Ltd CONB.NS:
CONCORD BIOTECH - GETS ABBREVIATED NEW DRUG APPLICATION APPROVAL FOR TOFACITINIB TABLETS, 5 MG AND 10 MG
CONCORD BIOTECH - RECEIVED APPROVAL FROM U.S. FOOD AND DRUG ADMINISTRATION FOR TOFACITINIB TABLETS
Source text: ID:nBSE9fqdg4
Further company coverage: CONB.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Concord Biotech
See all newsIndia's Concord Biotech rises after board to consider bonus share issue
Brief: Concord Biotech Ltd June-Quarter Consol Net Profit 585.3 Million Rupees
Brief: Concord Biotech Completes PPB (Kenya) And NDA (Uganda) Inspection At Unit-Ii Formulation Facility
Brief: Concord Biotech Completes Anvisa Inspection At Limbasi API Manufacturing Facility
India's Concord Biotech jumps to 4-month high after US FDA drug approval